Galux
PrivateLast Round
Series B
Feb 10, 2026
Total Funding Raised
$53.32M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Galux is a biotechnology company that has developed an AI-powered drug design platform to identify and create novel therapeutics for a variety of diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, ML Platforms
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Galux Comparables
Compare Galux with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nabla | 87% | |
| Genesis Molecular AI | 84% | |
| Scala Biodesign | 84% | |
Galux Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 10, 2026 | ||||
| VC Round | Oct 1, 2023 | ||||
| Series A | Oct 1, 2022 | ||||
| Seed | Dec 16, 2021 | ||||
| Pre Seed | Apr 1, 2021 |
Galux Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| InterVest | Series B, Seed, Series A, Pre Seed |
| SL Investment | Series B |
| DAYLI Partners | Series B |
| Pathway Capital Management | Series B, Series A |
| TKG Ventures | Series B |
| Mirae Asset Securities | Series B |
| NCORE Ventures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 16, 2026
Will attend and present at the AACR 2026 conference.
- Apr 16, 2026
Preclinical data on pd-1/il-18v immunocytokine to be presented at AACR 2026.
Galux Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Galux's valuation, stock price, and market status.